Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the rate of cryosurvival of mature oocytes following vitrification, and to then compare the reproductive potential of vitrified oocytes relative to those which have not been cryopreserved.


Clinical Trial Description

This study will recruit patients from the NY/NJ/CT/eastern PA area only.

Cryopreservation of human oocytes has a great potential to preserve or extend fertility in the face of disease whose treatment would result in a loss of ovarian function. (malignancy, severe autoimmune disease, etc.). It would also provide a means of quarantining oocytes to be used in oocyte donation to provide the lowest possible risk of infection.

There are two methods for storage of oocytes: slow freezing or vitrification. Slow freezing is the conventional method and has been successfully used for embryos since 1983 and more recently for oocytes. Recent reports indicate that vitrification may be more successful than slow freezing. However, the technique has not been rigorously validated to date. The aim of this study is to determine the rate of cryosurvival of mature oocytes following vitrification, and to then compare the reproductive potential of vitrified oocytes relative to those which have not been cryopreserved.

Patients will undergo ovarian stimulation for in vitro fertilization (IVF) according to the protocol recommended by their primary doctor. After retrieval, mature oocytes will be divided in half. One half will undergo vitrification, immediate thaw and intracytoplasmic sperm injection (ICSI). The other half will undergo just ICSI. All embryos will then develop on identical culture until day 3 or day 5. Prior to transfer, the best embryo from each group will undergo biopsy for genetic fingerprinting. The patient will have a 2 embryo transfer (one from each group). All extra embryos will be biopsied for pre-implantation genetic diagnosis (PGD) prior to being cryopreserved. If the patient becomes pregnant, we will follow up with an additional blood draw at approximately 9 weeks gestation and buccal swabs after the delivery of the infant(s). ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label


Related Conditions & MeSH terms


NCT number NCT01223118
Study type Interventional
Source Reproductive Medicine Associates of New Jersey
Contact
Status Completed
Phase N/A
Start date August 2010
Completion date July 2012

See also
  Status Clinical Trial Phase
Completed NCT01558141 - Follicular Flushing N/A
Not yet recruiting NCT04519918 - Clinical Application of Artificial Oocyte Activation Technique (AOA) in ART N/A
Recruiting NCT03810001 - Mechanical Stimulation Improve the Fertilization in ICSI Cycle N/A
Not yet recruiting NCT04523103 - Artificial Assisted Activation Following in Fertilization Failure N/A
Completed NCT00340587 - Human Sperm Binding to Transgenic Mouse Eggs
Completed NCT00598208 - A Phase 2, Trial to Investigate the Dose-Response Relationship of a Single Injection of Org 36286 (Corifollitropin Alfa) to Initiate Multiple Follicular Growth in a Controlled Ovarian (Study 38826)(P06055)(COMPLETED) Phase 2
Not yet recruiting NCT06433518 - BEst Size for Ovulation Triggering in Poseidon 4 Patients (BEST 4 Study)
Completed NCT02913781 - Polar Body Removal Before ICSI for Oocyte Activation in Previous Fertilization Failure Cases N/A
Recruiting NCT04537481 - Lipidic Differences of Sperm Between Normal and Low Fertilization Patients N/A